Vertex shares plunge after mix up with data analysis vendor

By Nick Taylor

- Last updated on GMT

Related tags Service provider Cystic fibrosis Clinical trial

Vertex shares plunge after mix up with data analysis vendor
Vertex shares plunged 10 per cent yesterday after a misunderstanding with its data analysis vendor led to it overstating results.

On May 7 shares in Vertex jumped by 50 per cent after it posted positive interim Phase II data for its cystic fibrosis therapy. Yesterday, however, the biotech made an embarrassing climb down when it said a mix up with its data analysis service provider led to it overstating the effect on patients.

This mistake is very disappointing, it’s unacceptable to us. It’s not how we do business at Vertex. This was a very unfortunate misinterpretation between us and an outside vendor​”, Jeffrey Leiden, CEO of Vertex, told investors in a conference call yesterday.

Vertex assumed the data its service provider sent was absolute. The data was actually relative. By reporting the relative data as absolute Vertex overstated the proportion of patients who achieved a five percentage point improvement in lung function by almost one-third.

While the data is still positive and Vertex plans to enter Phase III trials with the treatment, the error is an embarrassment, particularly for a biotech that has built its reputation on quality, cutting-edge science.

The Massachusetts-headquartered biotech took its share of the blame, instead of trying to pin the debacle on its service provider, and committed to improving communication with its data analysis vendor. “We’re taking steps to fix it and make sure it doesn’t happen again​”, Leiden said.

Outsourcing-Pharma asked Vertex if it will continue to work with the data analysis service provider but the biotech declined to give further information. “We are not providing any additional details at this time​”, Dawn Kalmar, director of product communications at Vertex, told Outsourcing-Pharma.

Since sharing interim results on May 7 the stock price of Vertex has increased by more than 70 per cent. After posting its correction yesterday shares in Vertex plunged by 20 per cent in pre-market trading and eventually closed down 11 per cent.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more